Company Encyclopedia
View More
name
Guobang Pharma
605507.SH
Guobang Pharma Ltd. engages in the research, development, production, and sale of products in the pharmaceutical and veterinary industries. The company offers pharmaceutical products, including quinolones, macrolides, cephalosporins, characteristic APIs, preparations and accessories, and key pharmaceutical intermediates; and mobile protection APIs, kinetophoretic preparations, and feed additives. It sells its products approximately in 115 countries and regions worldwide.
3.097 T
605507.SHMarket value -Rank by Market Cap -/-

Financial Score

21/12/2025 Update
B
PharmaceuticalsIndustry
Industry Ranking24/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE10.84%B
    • Profit Margin14.69%B
    • Gross Margin27.62%C
  • Growth ScoreC
    • Revenue YoY4.00%C
    • Net Profit YoY24.30%B
    • Total Assets YoY-0.51%D
    • Net Assets YoY5.47%B
  • Cash ScoreC
    • Cash Flow Margin680.74%C
    • OCF YoY4.00%C
  • Operating ScoreC
    • Turnover0.56C
  • Debt ScoreA
    • Gearing Ratio21.78%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Guobang Pharma has repurchased a total of 5.3753 million shares, costing 103 million yuan

    According to the Zhitong Finance APP, Guobang Pharma announced that as of October 31, 2025, the company has repurchased a total of 5.3753 million shares through centralized bidding, accounting for 0.96% of the company's total share capital. The highest transaction price was RMB 19.88 per share, the lowest price was RMB 18.61 per share, and the total amount paid was RMB 103 million (excluding transaction fees)

    Zhitong·
    SH
    605507
    -0.04%
    Zhitong·
    SH
    605507
    -0.04%

    Guobang Pharma Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025

    Guobang Pharma Ltd. reported its earnings for the nine months ending September 30, 2025. The company achieved sales of CNY 4,469.88 million, up from CNY 4,418.15 million the previous year. Net income rose to CNY 670.24 million from CNY 578.88 million year-over-year. Basic and diluted earnings per share from continuing operations both increased to CNY 1.21, compared to CNY 1.04 a year ago.

    marketscreener·
    SH
    605507
    -0.04%
    marketscreener·
    SH
    605507
    -0.04%

    Guobang Pharma released its performance for the first three quarters, with a net profit attributable to the parent company of 670 million yuan, a year-on-year increase of 15.78%

    According to the Zhitong Finance APP, Guobang Pharma released its third-quarter report for 2025. In the first three quarters, the company achieved operating revenue of 4.47 billion yuan, a year-on-year increase of 1.17%. The net profit attributable to shareholders of the listed company was 670 million yuan, a year-on-year increase of 15.78%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 619 million yuan, a year-on-year increase of 9.59%

    Zhitong·
    SH
    605507
    -0.04%
    Zhitong·
    SH
    605507
    -0.04%

    Guobang Pharma: Cumulatively repurchased 0.96% of the company's shares, costing 103 million yuan

    Guobang Pharma announced that as of July 31, 2025, the company has repurchased a total of 5.3753 million shares through centralized bidding, accounting for 0.96% of the company's total share capital. The highest transaction price was RMB 19.88 per share, and the lowest price was RMB 18.61 per share, with a total amount paid of RMB 103 million. The total amount of funds for this repurchase is between RMB 100 million and RMB 200 million, with a repurchase price not exceeding RMB 25 per share, and the repurchase period is from March 11, 2025, to March 10, 2026

    Zhitong·
    SH
    605507
    -0.04%
    Zhitong·
    SH
    605507
    -0.04%

    Guobang Pharma released its performance for the first half of the year, with a net profit attributable to the parent company of 456 million yuan, an increase of 12.60%

    Guobang Pharma released its 2025 semi-annual report, with operating revenue of 3.026 billion yuan, a year-on-year increase of 4.63%; net profit attributable to the parent company was 456 million yuan, a year-on-year increase of 12.60%. The net profit excluding non-recurring gains and losses was 436 million yuan, a year-on-year increase of 10.33%. The basic earnings per share were 0.82 yuan. The company has achieved significant results in the fields of pharmaceuticals, animal health, and plant protection, with fluoroquinolone shipments exceeding 2,000 tons, and hydrochloride doxycycline approved for CEP certification, while the Qidele series of health drinks has been launched in the market

    Zhitong·
    SH
    605507
    -0.04%
    Zhitong·
    SH
    605507
    -0.04%
    © 2025 Longbridge｜Disclaimer